Click on headlines below to download research
Termination of coverage
Termination of coverage - Sequana Medical | 02/02/2024
Edison Investment Research is terminating coverage on Sequana Medical (SEQUA). Please note you should no longer rely on any previous research or estimates…
Sequana Medical - Executive interview
Sequana Medical - executive interview | 26/01/2024
Based in Belgium, Sequana Medical develops and commercialises products to treat diuretic-resistant fluid overload, a frequent complication of liver disease…
New CPT III codes to support reimbursement
Sequana Medical | 05/01/2024
Sequana Medical announced that the American Medical Association has issued six new Category III Current Procedural Terminology (CPT III) codes for the…
PMA application submitted to FDA for alfapump
Sequana Medical | 03/01/2024
Sequana Medical announced in late December that it has submitted a Premarket Approval (PMA) application to the US FDA regarding its alfapump device for…
Positive data in non-randomised MOJAVE cohort
Sequana Medical | 04/12/2023
Sequana Medical has announced interim results from all three patients comprising the non-randomised cohort of its MOJAVE US Phase I/IIa study evaluating…
MOJAVE early efficacy validates DSR 2.0
Sequana Medical | 13/11/2023
Sequana Medical recently announced positive interim data, from the non-randomised cohort of the Phase I/IIa MOJAVE study, in patients with chronic heart…